Amikacin population pharmacokinetics among paediatric burn patients

Burns

Volumn 40, Issue 2, 2014, Pages 311-318

  Sherwin, Catherine M T ^a   Wead, Stephanie ^b   Stockmann, Chris ^a   Healy, Daniel ^b,c   Spigarelli, Michael G ^a   Neely, Alice ^b,c   Kagan, Richard ^b,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

Amikacin; Paediatric burns; Pharmacokinetics

Indexed keywords

AMIKACIN; C REACTIVE PROTEIN; CREATININE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ADOLESCENT; ARTICLE; BODY HEIGHT; BODY WEIGHT; BURN; BURN INFECTION; BURN PATIENT; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; HOSPITALIZED CHILD; HUMAN; INFANT; LUNG BURN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SEPSIS; THROMBOCYTE COUNT; TREATMENT OUTCOME;

AMIKACIN; PAEDIATRIC BURNS; PHARMACOKINETICS;

ADOLESCENT; AMIKACIN; ANTI-BACTERIAL AGENTS; BODY SURFACE AREA; BODY WEIGHT; BURNS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; MALE; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; SEPSIS; VANCOMYCIN;

EID: 84893783743     PISSN: 03054179     EISSN: 18791409     Source Type: Journal    
DOI: 10.1016/j.burns.2013.06.015     Document Type: Article

References (46)

1. D.E. Zaske, R.J. Sawchuk, and R.G. Strate The necessity of increased doses of amikacin in burn patients Surgery 84 1978 603 608
2. T.T. Nguyen, D.A. Gilpin, N.A. Meyer, and D.N. Herndon Current treatment of severely burned patients Ann Sur 223 1996 14 25
3. M.J. Weinbren Pharmacokinetics of antibiotics in burn patients J Antimicrob Chemother 44 1999 319 327
4. B.D. Smeltzer, M.S. Schwartzman, and J.S. Bertino Jr. Amikacin pharmacokinetics during continuous ambulatory peritoneal dialysis Antimicrob Agents Chemother 32 1988 236 240
5. B.A. Boucher, D.A. Kuhl, and W.L. Hickerson Pharmacokinetics of systemically administered antibiotics in patients with thermal injury Clinical Infect Dis 14 1992 458 463
6. U. Jaehde, and F. Sorgel Clinical pharmacokinetics in patients with burns Clin Pharmacokinet 29 1995 15 28
7. R.G. Kopcha, W.K. Fant, and G.D. Warden Increased dosing requirements for amikacin in burned children J Antimicrob Chemother 28 1991 747 752
8. M.Z. Ali, and M.B. Goetz A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides Clin Infect Dis 24 1997 796 809
9. R. Garraffo, H.B. Drugeon, P. Dellamonica, E. Bernard, and P. Lapalus Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity Antimicrob Agents Chemother 34 1990 614 621
10. B. Blanchet, V. Jullien, C. Vinsonneau, and M. Tod Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients Clin Pharmacokin 47 2008 635 654
11. D.S. Burgess Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections Clin Infect Dis 40 Suppl. 2 2005 S99 S104
12. G.L. Daikos, G.G. Jackson, V.T. Lolans, and D.M. Livermore Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation J Infect Dis 162 1990 414 420
13. D.N. Fisman, and K.M. Kaye Once-daily dosing of aminoglycoside antibiotics Infect Dis Clin N Am 14 2000 475 487
14. J.A. Karlowsky, S.A. Zelenitsky, and G.G. Zhanel Aminoglycoside adaptive resistance Pharmacotherapy 17 1997 549 555
15. G.L. Daikos, V.T. Lolans, and G.G. Jackson First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use Antimicrob Agents Chemother 35 1991 117 123
16. G. Kahlmeter, and J.I. Dahlager Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982 J Antimicrob Chemother 13 (Suppl. A) 1984 9 22
17. M.E. De Broe, L. Verbist, and G.A. Verpooten Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man J Antimicrob Chemother 27 (Suppl. C) 1991 41 47
18. A. Contrepois, N. Brion, J.J. Garaud, F. Faurisson, F. Delatour, and J.C. Levy et al. Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans Antimicrob Agents Chemother 27 1985 520 524
19. P.D. Williams, D.B. Bennett, C.R. Gleason, and G.H. Hottendorf Correlation between renal membrane binding and nephrotoxicity of aminoglycosides Antimicrob Agents Chemother 31 1987 570 574
20. Y. Chen, W.G. Huang, D.J. Zha, J.H. Qiu, J.L. Wang, and S.H. Sha et al. Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic Hear Res 226 2007 178 182
21. R.E. Black, W.K. Lau, R.J. Weinstein, L.S. Young, and W.L. Hewitt Ototoxicity of amikacin Antimicrob Agents Chemother 9 1976 956 961
22. M.L. Barclay, C.M. Kirkpatrick, and E.J. Begg Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokin 36 1999 89 98
23. R. Ferriols-Lisart, and M. Alos-Alminana Effectiveness and safety of once-daily aminoglycosides: a meta-analysis Am J Health Syst Pharm 53 1996 1141 1150
24. M.E. Jolley, S.D. Stroupe, C.H. Wang, H.N. Panas, C.L. Keegan, and R.L. Schmidt et al. Fluorescence polarization immunoassay. I. Monitoring aminoglycoside antibiotics in serum and plasma Clin Chem 27 1981 1190 1197
25. E.I. Ette, and P.J. Williams Population pharmacokinetics I: background, concepts, and models Ann Pharmacother 38 2004 1702 1706
26. W.M. Kirby, J.T. Clarke, R.D. Libke, and C. Regamey Clinical pharmacology of amikacin and kanamycin J Infect Dis 134 (Suppl.) 1976 S312 S315
27. P. Van der Auwera Pharmacokinetic evaluation of single daily dose amikacin J Antimicrob Chemother 27 (Suppl. C) 1991 63 71
28. J.M. Walker, R. Wise, and M. Mitchard The pharmacokinetics of amikacin and gentamicin in volunteers: a comparison of individual differences J Antimicrob Chemother 5 1979 95 99
29. K.S. Akers, J.M. Cota, C.R. Frei, K.K. Chung, K. Mende, and C.K. Murray Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration Antimicrob Agents Chemother 55 2011 4639 4642
30. J.M. Conil, B. Georges, A. Breden, C. Segonds, M. Lavit, and T. Seguin et al. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen Int J Antimicrob Agents 28 2006 226 230
31. D.E. Zaske, R.G. Strate, and P.R. Kohls Amikacin pharmacokinetics: wide interpatient variation in 98 patients J Clin Pharmacol 31 1991 158 163
32. F. Bressolle, A. Gouby, J.M. Martinez, P. Joubert, G. Saissi, and R. Guillaud et al. Population pharmacokinetics of amikacin in critically ill patients Antimicrob Agents Chemother 40 1996 1682 1689
33. S. Romano, M.M. Fdez de Gatta, M.V. Calvo, D. Caballero, A. Dominguez-Gil, and J.M. Lanao Population pharmacokinetics of amikacin in patients with haematological malignancies J Antimicrob Chemother 44 1999 235 242
34. C.M. Sherwin, S. Svahn, A. Van der Linden, R.S. Broadbent, N.J. Medlicott, and D.M. Reith Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis Eur J Clin Pharmacol 65 2009 705 713
35. R.J. Sawchuk, and D.E. Zaske Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients J Pharmacokin Biopharm 4 1976 183 195
36. D.E. Zaske, R.J. Sawchuk, D.N. Gerding, and R.G. Strate Increased dosage requirements of gentamicin in burn patients J Trauma 16 1976 824 828
37. R.F. De Cock, K. Allegaert, M.F. Schreuder, C.M. Sherwin, M. de Hoog, and J.N. van den Anker et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance Clin Pharmacokin 51 2012 105 117
38. R.H. Yang, X.Z. Rong, R. Hua, and T. Zhang Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn Burns 35 2009 75 79
39. M. Drozdzik, L. Domanski, J. Wojcicki, B. Gawronska-Szklarz, P. Machoy, and A. Pudlo Effect of unilateral nephrectomy on the pharmacokinetics of amikacin in humans J Pharm Pharmacol 54 2002 509 514
40. R.L. Davis, D. Lehmann, C.A. Stidley, and J. Neidhart Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy Antimicrob Agents Chemother 35 1991 944 947
41. M. Barza, and M. Lauermann Why monitor serum levels of gentamicin? Clin Pharmacokin 3 1978 202 215
42. E. Hassan, and J.D. Ober Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients Antimicrob Agents Chemother 31 1987 1855 1858
43. R.D. Moore, P.S. Lietman, and C.R. Smith Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration J Infect Dis 155 1987 93 99
44. D.F. Gaieski, M.E. Mikkelsen, R.A. Band, J.M. Pines, R. Massone, and F.F. Furia et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department Crit Care Med 38 2010 1045 1053
45. C.I. Kang, S.H. Kim, H.B. Kim, S.W. Park, Y.J. Choe, and M.D. Oh et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome Clin Infect Dis 37 2003 745 751
46. E.I. Ette Stability and performance of a population pharmacokinetic model J Clin Pharmacol 37 1997 486 495